BioLight Life Sciences has announced the formation of its new Scientific Advisory Board consisting of internationally recognized scientific, medical experts and business key opinion leaders in the field of ophthalmology.
The new Scientific Advisory Board is comprised of following members:
Dr. Vincente Anido Jr. is an ophthalmology industry leader. In his recent role, he served as the CEO and Chairman of the Board of Aerie pharmaceuticals, an ophthalmic pharmaceutical company. Prior to Aerie, he led several companies including in his role as the CEO of ISTA Pharmaceuticals, that was acquired by Bausch + Lomb. He holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City. Dr. Anido Jr. is also nominated as Special Strategic Advisor of ViSci Ltd., a subsidiary of BioLight.
Dr. Jeffrey Goldberg is a Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve. Dr. Goldberg is also the co-founder of Peripherex, one of BioLight’s portfolio companies engaged in solutions for remote diagnosis of peripheral vision impairment. Dr. Goldberg received his B.S. magna cum laude from Yale University, and his MD and PhD from Stanford University where he made significant discoveries about the failure of optic nerve regeneration.
Professor Anat Loewenstein is the Chairwoman of the Department of Ophthalmology at Ichilov Sourasky Medical Center Tel Aviv, a leading center for diagnosing and treating a complete spectrum of ophthalmological diseases and Chairwoman of the Israeli Ophthalmological Society. She also serves as Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University. Anat is involved in numerous leading ophthalmic companies (such as Notal Vision) in various roles.
Dr. Ron Neumann, BioLight’s Chief Medical Officer (CMO), is a leading expert ophthalmologist, specializing in inflammatory eye disease. He has served as a Chief Fellow at the Harvard University’s Eye and Ear Infirmary, established a Clinic for Inflammatory Eye Diseases at Sheba Medical Hospital and has held various senior positions including serving as the Global Medical Director for Teva Pharmaceuticals of Innovative Products. Dr. Neumann serves as a special consultant in inflammatory eye disease to Maccabi; Israel’s leading HMO.
Dr. Joseph Tauber, is an internationally recognized authority in the field of ocular surface diseases. He has been a Principal Investigator in dozens of clinical research programs, including those that led to the approval of the only two medications approved by the FDA for the treatment of dry eye. Dr. Tauber received his doctorate from Harvard Medical School, his training in internal medicine at Beth Israel Hospital and in ophthalmology at Tufts-New England Medical Center.
